Cambridge Massachusetts

Bluebird analysis finds gene therapy ‘very unlikely’ to be cause of patient’s cancer

Bluebird bio said independent analyses found that the gene therapy inserted its payload at a site not known to cause cancer. Based on the results, the company has asked the FDA for permission to resume all of the clinical trials that were placed on hold in February during the inquiry.

Beam makes $120M bet that GuideTx’s tech brings gene editing beyond the liver

Base-editing biotech Beam Therapeutics engineered an all-stock buyout of Guide Therapeutics, a startup that finds, in vivo, the lipid nanoparticles that can deliver genetic medicines. Beam said GuideTx’s tech helps it address tissue types throughout the body, not just the liver.

KalVista Pharma plans pivotal test after HAE drug posts positive Phase 2 data

One year after losing Merck as a partner, KalVista reports mid-stage clinical data for a pill that could offer an alternative to injectable drugs for a rare, potentially life-threatening disease. KalVista plans to meet with the FDA about proceeding to a Phase 3 study.

Glympse Bio raises more than $46M in Series B round for biosensor technology

The company is developing biosensors, initially for NASH, that could be used in place of liver biopsy and have applicability in development of drugs for the disease.